Previous 10 | Next 10 |
Atossa Genetics (NASDAQ: ATOS ): FY GAAP EPS of -$2.03 in-line. More news on: Atossa Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SEATTLE, March 26, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the fourth quarter an...
Atossa Therapeutics (NASDAQ: ATOS ) is scheduled to meet with the FDA on April 30 to discuss the development path for oral Endoxifen for reducing mammographic breast density. More news on: Atossa Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SEATTLE, March 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that it will meet with the U.S. FDA on Apri...
SEATTLE, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO will present a corporate...
Every February 4th is World Cancer Day , the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalyzing personal, collective, and government action, they are working to reimagine a world where millio...
Atossa Therapeutics ( ATOS ) has had some notable spikes in its share price over the past couple of years, which has put the ticker near the top of my speculative watch list. Unfortunately, Atossa has been "too early" in its development for me to consider an investment; however, the company ha...
SEATTLE, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders: To Our Valued Shareholders: I begin this letter with a sense of great pride about our accomplishmen...
SEATTLE, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that its corporate name change from "Atossa ...
Atossa Genetics (NASDAQ: ATOS ) has signed a contract with Stockholm South General Hospital in Sweden to conduct a Phase 2 study of Atossa’s oral Endoxifen to reduce mammographic breast density (MBD) in women. More news on: Atossa Genetics Inc., Healthcare stocks news, Read mo...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...